Inventor · disambiguated record
Benoit Smagghe
Also filed as: SMAGGHE BENOIT · SMAGGHE BENOIT J
12 granted patents·23 pending applications·34 citations·filing 2013–2025
88Inventor score
Files withMINERVA BIOTECHNOLOGIES CORP35
Top patents by PatentIndex Score
35 records- 0196US12115192B2Chimeric antigen receptor compositions and methods for treating MUC1* diseasesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Granted Oct 15, 2024·3 cites·39 claims
- 0296US11976295B2Media for stem cell proliferation and inductionMINERVA BIOTECHNOLOGIES CORP·Filed 2023·Granted May 7, 2024·4 cites·19 claims
- 0395US12049514B2Anti-NME antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Jul 30, 2024·3 cites·16 claims
- 0495US12037413B2Anti-NME antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Jul 16, 2024·3 cites·28 claims
- 0595US12006371B2Humanized anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2022·Granted Jun 11, 2024·3 cites·29 claims
- 0695US11897967B2Humanized anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2022·Granted Feb 13, 2024·3 cites·30 claims
- 0794US11746159B2Humanized anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2016·Granted Sep 5, 2023·8 cites·13 claims
- 0888US11702483B2Method of treating an NME7 expressing cancer with a peptideMINERVA BIOTECHNOLOGIES CORP·Filed 2018·Granted Jul 18, 2023·2 cites·7 claims
- 0987US11591565B2Media for stem cell proliferation and inductionMINERVA BIOTECHNOLOGIES CORP·Filed 2014·Granted Feb 28, 2023·5 cites·19 claims
- 1087US2024277803A1Nme inhibitors and methods of using nme inhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 1184US2025026853A1Humanized anti-muc1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 1281US12415868B1Anti-NME antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Granted Sep 16, 2025·0 cites·9 claims
- 1381US2024424025A1Chimeric antigen receptor compositions and methods for treating muc1* diseasesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 1480US2024392038A1Anti-nme antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 1580US2024294590A1Nucleic acid encoding genetically engineered growth factor variantsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 1679US2024261406A1Chimeric antigen receptor compositions and methods for treating muc1* diseasesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 1778US2022218846A1Nme inhibitors and methods of using nme inhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 1876US2022089779A1Nme inhibitors and methods of using nme inhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 1975US12479928B2Anti-cancer peptideMINERVA BIOTECHNOLOGIES CORP·Filed 2022·Granted Nov 25, 2025·0 cites·20 claims
- 2074US2025121088A1Anti-muc1* antibody drug complexes and uses thereofMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 2170US2024247229A1Media for stem cell proliferation and inductionMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 2267US2025276016A1Chimeric antigen receptor and il-18 receptor compositions and methods of use thereinMINERVA BIOTECHNOLOGIES CORP·Filed 2023·Application pending·0 cites
- 2364US2023242678A1Anti-nme antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 2464US2021308213A1Method for diagnosing and treating cancer using naïve state stem cell specific genesMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 2562US12491259B2Anti-variable MUC1* antibodies and uses thereofMINERVA BIOTECHNOLOGIES CORP·Filed 2023·Granted Dec 9, 2025·0 cites·20 claims
- 2662US2025255982A1Anti-muc1* antibody drug complexes and uses thereofMINERVA BIOTECHNOLOGIES CORP·Filed 2025·Application pending·0 cites
- 2758US2020062812A1Nucleic acid encoding genetically engineered growth factor variantsMINERVA BIOTECHNOLOGIES CORP·Filed 2019·Application pending·0 cites
- 2856US2014065113A1Genetically engineered growth factor variantsMINERVA BIOTECHNOLOGIES CORP·Filed 2013·Application pending·0 cites
- 2956US2024390418A1Anti-variable muc1* antibodies and uses thereofMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 3053US2017106046A1Method for diagnosing and treating cancer using naive state stem cell specific genesMINERVA BIOTECHNOLOGIES CORP·Filed 2016·Application pending·0 cites
- 3153US2018258186A1NME Inhibitors and Methods of Using NME InhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2018·Application pending·0 cites
- 3251US2016326263A1NME Inhibitors and Methods of Using NME InhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2015·Application pending·0 cites
- 3346US2017204196A1Anti-nme antibodyMINERVA BIOTECHNOLOGIES CORP·Filed 2015·Application pending·0 cites
- 3446US2018235193A1Method of stem cell-based organ and tissue generationMINERVA BIOTECHNOLOGIES CORP·Filed 2016·Application pending·0 cites
- 3541US2019290692A1Humanized anti-muc1* antibodies and use of cleavage enzymeMINERVA BIOTECHNOLOGIES CORP·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Benoit Smagghe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →